Literature DB >> 12125976

The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal.

Joon-Khim Loh1, Shiuh-Lin Hwang, Ann-Shung Lieu, Tzuu-Yuan Huang, Shen-Long Howng.   

Abstract

BACKGROUND: Both experimental and human tumors often synthesize high levels of prostaglandins, most notably prostaglandin E2 (PGE2). This compound may play an important role in tumor growth and immunosuppression. Little is known of the production of PGE2 by brain tumors. The present study was designed to investigate the levels of PGE2 in the plasma of human brain tumors before and after tumor removal.
METHODS: The plasma PGE2 levels of brain tumors before and after tumor removal were measured by high-performance liquid chromatography (HPLC).
RESULTS: There is a significantly high concentration of PGE2 in malignant brain tumor before tumor removal. Significantly decrease of PGE2 concentration after total removal of the tumor was found both in the malignant and benign brain tumor groups (P = 0.0001 and P = 0.0039 respectively). However, compared to the control group, only malignant brain tumor showed a significant decrease of PGE2 concentration after tumor removal (P = 0.0009).
CONCLUSION: Our study demonstrates the malignant brain tumor synthesized higher relative proportions of PGE2 and surgical removal of the brain tumor can reduce the production of PGE2.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12125976     DOI: 10.1023/a:1015782809966

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

1.  Inhibition of lymphocyte responsiveness by a glial tumor cell-derived suppressive factor.

Authors:  T L Roszman; W H Brooks; L H Elliott
Journal:  J Neurosurg       Date:  1987-12       Impact factor: 5.115

2.  Prostaglandin E2 levels in human brain tumor tissues and arachidonic acid levels in the plasma membrane of human brain tumors.

Authors:  E Kökoğlu; Y Tüter; K S Sandikçi; Z Yazici; E Z Ulakoğlu; H Sönmez; E Ozyurt
Journal:  Cancer Lett       Date:  1998-10-23       Impact factor: 8.679

Review 3.  The estimation of catecholamines in human plasma.

Authors:  J M Holly; H L Makin
Journal:  Anal Biochem       Date:  1983-02-01       Impact factor: 3.365

4.  Malignant glioma modulation of immune function: relative contribution of different soluble factors.

Authors:  W T Couldwell; P Dore-Duffy; M L Apuzzo; J P Antel
Journal:  J Neuroimmunol       Date:  1991-08       Impact factor: 3.478

5.  Immunobiology of primary intracranial tumors. Part 1: studies of the cellular and humoral general immune competence of brain-tumor patients.

Authors:  M S Mahaley; W H Brooks; T L Roszman; D D Bigner; L Dudka; S Richardson
Journal:  J Neurosurg       Date:  1977-04       Impact factor: 5.115

6.  Investigations of catecholamine metabolism using high-performance liquid chromatography: analytical methodology and clinical applications.

Authors:  A M Krstulović
Journal:  J Chromatogr       Date:  1982-04-16

7.  Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta.

Authors:  A Koff; M Ohtsuki; K Polyak; J M Roberts; J Massagué
Journal:  Science       Date:  1993-04-23       Impact factor: 47.728

8.  Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2.

Authors:  C M Hilkens; H Vermeulen; R J van Neerven; F G Snijdewint; E A Wierenga; M L Kapsenberg
Journal:  Eur J Immunol       Date:  1995-01       Impact factor: 5.532

9.  Prostaglandin and thromboxane synthesis by human intracranial tumors.

Authors:  M G Castelli; C Chiabrando; R Fanelli; L Martelli; G Butti; P Gaetani; P Paoletti
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

Review 10.  Molecular profile of reactive astrocytes--implications for their role in neurologic disease.

Authors:  M Eddleston; L Mucke
Journal:  Neuroscience       Date:  1993-05       Impact factor: 3.590

View more
  16 in total

1.  Physiological Concentration of Prostaglandin E2 Exerts Anti-inflammatory Effects by Inhibiting Microglial Production of Superoxide Through a Novel Pathway.

Authors:  Shih-Heng Chen; Yueh-Feng Sung; Esteban A Oyarzabal; Yu-Mei Tan; Jeremy Leonard; Mingri Guo; Shuo Li; Qingshan Wang; Chun-Hsien Chu; Shiou-Lan Chen; Ru-Band Lu; Jau-Shyong Hong
Journal:  Mol Neurobiol       Date:  2018-03-01       Impact factor: 5.590

2.  Analgesic use and the risk of primary adult brain tumor.

Authors:  Kathleen M Egan; Louis B Nabors; Zachary J Thompson; Carrie M Rozmeski; Gabriella A Anic; Jeffrey J Olson; Renato V LaRocca; Sajeel A Chowdhary; Peter A Forsyth; Reid C Thompson
Journal:  Eur J Epidemiol       Date:  2016-02-19       Impact factor: 8.082

3.  Evaluation of WO 2012/177618 A1 and US-2014/0179750 A1: novel small molecule antagonists of prostaglandin-E2 receptor EP2.

Authors:  Thota Ganesh
Journal:  Expert Opin Ther Pat       Date:  2015-03-15       Impact factor: 6.674

Review 4.  Cyclooxygenase-2 in glioblastoma multiforme.

Authors:  Jiange Qiu; Zhi Shi; Jianxiong Jiang
Journal:  Drug Discov Today       Date:  2016-09-28       Impact factor: 7.851

5.  Prostaglandin E2 released from activated microglia enhances astrocyte proliferation in vitro.

Authors:  Dan Zhang; Xiaoming Hu; Li Qian; Belinda Wilson; Christopher Lee; Patrick Flood; Robert Langenbach; Jau-Shyong Hong
Journal:  Toxicol Appl Pharmacol       Date:  2009-05-03       Impact factor: 4.219

6.  Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.

Authors:  Ninib Baryawno; Baldur Sveinbjörnsson; Staffan Eksborg; Abiel Orrego; Lova Segerström; Carl Otto Oqvist; Stefan Holm; Bengt Gustavsson; Bertil Kågedal; Per Kogner; John Inge Johnsen
Journal:  Neuro Oncol       Date:  2008-08-20       Impact factor: 12.300

Review 7.  The eicosanoid cascade: possible role in gliomas and meningiomas.

Authors:  N Nathoo; G H Barnett; M Golubic
Journal:  J Clin Pathol       Date:  2004-01       Impact factor: 3.411

Review 8.  The molecular profile of microglia under the influence of glioma.

Authors:  Wei Li; Manuel B Graeber
Journal:  Neuro Oncol       Date:  2012-05-09       Impact factor: 12.300

9.  Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.

Authors:  Jianxiong Jiang; Ray Dingledine
Journal:  J Pharmacol Exp Ther       Date:  2012-11-28       Impact factor: 4.030

Review 10.  Tumor cells and tumor-associated macrophages: secreted proteins as potential targets for therapy.

Authors:  Marc Baay; Anja Brouwer; Patrick Pauwels; Marc Peeters; Filip Lardon
Journal:  Clin Dev Immunol       Date:  2011-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.